Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) shares crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.63 and traded as high as $5.17. Cumberland Pharmaceuticals shares last traded at $5.08, with a volume of 11,577 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 8th.

Cumberland Pharmaceuticals Stock Performance

The company has a market capitalization of $76.15 million, a PE ratio of -6.61 and a beta of -0.35. The firm has a 50-day moving average of $4.66 and a two-hundred day moving average of $3.68. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Institutional Trading of Cumberland Pharmaceuticals

Several institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Cumberland Pharmaceuticals in the 1st quarter valued at approximately $634,000. Walleye Capital LLC acquired a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at approximately $298,000. Berkshire Asset Management LLC PA acquired a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at approximately $692,000. Informed Momentum Co LLC purchased a new stake in Cumberland Pharmaceuticals in the first quarter valued at approximately $304,000. Finally, Two Sigma Investments LP lifted its stake in Cumberland Pharmaceuticals by 94.3% during the fourth quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company's stock worth $89,000 after purchasing an additional 18,271 shares in the last quarter. Hedge funds and other institutional investors own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.